Want to see SE:ICO full AI Analyst Report?

Iconovo AB (ICO) Price & Analysis

1 Followers

ICO Stock Chart & Stats

kr1.12

-kr0.10(-3.02%)

At close: Mar 06 4:00 PM EST

kr1.12

-kr0.10(-3.02%)

Day’s Range― - ―

52-Week Rangekr0.91 - kr2.79

Previous CloseN/A

Volume7.53K

Average Volume (3M)46.24K

Market Cap

kr79.66M

Enterprise Valuekr22.12M

Total Cash (Recent Filing)kr49.25M

Total Debt (Recent Filing)kr5.70M

Price to Earnings (P/E)―

Beta-0.27

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding74,800,380

10 Day Avg. Volume58,575

30 Day Avg. Volume46,237

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.37

Price to Sales (P/S)39.24

P/FCF Ratio-0.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)kr29.00M

Bulls Say, Bears Say

Bulls Say

Licensing, Partnership-driven Business ModelA licensing and partnership model is capital-efficient and durable: milestone and royalty structures can generate high-margin, scalable revenue without the company bearing full commercialization costs. Over 2–6 months this supports lower capex needs and creates long-term upside tied to partner commercialization.

Specialized Inhaler Platform And IP FocusA focused platform for inhalation devices builds a specialist competitive advantage: device IP, regulatory know-how and co-development capabilities raise switching costs and foster long-term partner relationships. This structural specialization supports durable deal flow and licensing opportunities once validated by partners.

Supportive Balance Sheet With Low LeverageLow leverage and a sizable equity cushion materially reduce refinancing risk and provide runway to fund development and partner projects. This structural balance-sheet strength gives the company flexibility to fund milestones or absorb timing lags in partner payments without immediate solvency pressure.

Bears Say

Persistent Negative Cash GenerationSustained negative operating and free cash flow is a structural constraint: it forces reliance on external financing or partner upfronts, which can dilute shareholders or add covenants. Over months, continued burn narrows strategic options and can delay or limit investment in development and commercialization.

Negative Gross Profit And Heavy Operating LossesNegative gross profit indicates core unit economics are not yet proven and operating losses show the business does not cover its cost base. This structural profitability weakness must be resolved via partnerships or scale; otherwise the company risks persistent value erosion and constrained ability to fund growth.

Deeply Negative Returns On EquityA ~-34% ROE reflects capital destruction and signals that deployed capital is not generating returns. Persistently negative ROE makes raising new capital more costly, limits investor appetite, and highlights structural issues in converting R&D and partnerships into profitable, scalable revenue.

ICO FAQ

What was Iconovo AB’s price range in the past 12 months?

Iconovo AB lowest stock price was kr0.91 and its highest was kr2.79 in the past 12 months.

What is Iconovo AB’s market cap?

Iconovo AB’s market cap is kr79.66M.

When is Iconovo AB’s upcoming earnings report date?

Iconovo AB’s upcoming earnings report date is Aug 20, 2026 which is in 41 days.

How were Iconovo AB’s earnings last quarter?

Iconovo AB released its earnings results on Apr 24, 2026. The company reported -kr0.105 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.105.

Is Iconovo AB overvalued?

According to Wall Street analysts Iconovo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Iconovo AB pay dividends?

Iconovo AB does not currently pay dividends.

What is Iconovo AB’s EPS estimate?

Iconovo AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iconovo AB have?

Iconovo AB has 74,800,380 shares outstanding.

What happened to Iconovo AB’s price movement after its last earnings report?

Iconovo AB reported an EPS of -kr0.105 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.478%.

Which hedge fund is a major shareholder of Iconovo AB?

Currently, no hedge funds are holding shares in SE:ICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iconovo AB

Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.